Replies to post #136397 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Solanezumab as acBACE inhibitor and it’s Amyloid target failure should be well know and much much more so than Anavex, yet a recently IPO’d biotech with similar approach is bought by Takeda.

I’m sure they know something I don’t, perhaps to do with smaller dose more of which passes the blood-brain-barrier with the Danali technology.

Still I’d rather take by bets on our presumed to be little known Anavex.

Only time will tell.

[Investor2014]

Don’t know, but since Denali’s AD pipeline is still preclinical you’d have to arm yourself with patience to find out.